Drug intelligence / Profile preview

SIINFEKL-P30

Development stage
Preclinical
Lead developer
Vaxil Bio
Modality
Vaccines & Immunotherapeutics, Peptides
Administration
Subcutaneous, Intradermal, Intramuscular
01

Overview

SIINFEKL-P30 is a chimeric peptide vaccine construct used primarily as a model in immunological research to study the enhancement of CD8+ T-cell responses. It consists of the MHC class I-restricted epitope SIINFEKL (derived from chicken ovalbumin, residues 257–264) fused or conjugated to the P30 universal T-helper epitope (derived from tetanus toxin, residues 947–967). The P30 sequence provides potent CD4+ T-cell help, which is critical for the induction and maintenance of robust SIINFEKL-specific cytotoxic T-lymphocyte (CTL) responses. This construct is frequently employed in preclinical studies to evaluate novel vaccine delivery platforms, adjuvants, and the mechanisms of T-cell activation and memory formation in murine models, specifically those expressing the H-2Kb MHC molecule.

Other names
OVA-P30 peptideOVA-P-30 peptideOVA-P 30 peptideSIINFEKL-tetanus toxin P30 conjugateSIINFEKL-P30 chimeric peptideSIINFEKL-P-30 chimeric peptideSIINFEKL-P 30 chimeric peptide
02

Targets

H-2KbMHC II (Major histocompatibility complex class II receptor)T-cell receptor specific for H-2Kb–SIINFEKL (OT-I TCR)TCR-P30 (T-cell receptor specific for MHC class II-tetanus toxin P30 peptide complex)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on SIINFEKL-P30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIINFEKL-P30.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call